Aurobindo Pharma USA Inc recalls
4 notices naming Aurobindo Pharma USA Inc as the recalling firm, since December 11, 2024. A notice covers specific products and lots, not every product of the firm.
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
Aurobindo Pharma USA Inc: Dicyclomine Hydrochloride Capsules
Hazard (FDA): shortfill; reports of empty capsules.
FDAMedicines
Aurobindo Pharma USA Inc: Acetaminophen Tablets
Hazard (FDA): cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).
FDAMedicines
Aurobindo Pharma USA Inc: Nebivolol Tablets
Hazard (FDA): CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.
FDAMedicines
Aurobindo Pharma USA Inc: Cinacalcet Tablets and 2 more
Hazard (FDA): cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
FDAMedicines